Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of apraglutide in short bowel syndrome with intestinal failure
jRCT2031220255Active, not recruiting
- Sponsor
- VectivBio
- Start
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Open-label, single-arm trial of apraglutide in short bowel syndrome (SBS) and intestinal failure (IF), sponsored by VectivBio. Primary endpoints: Adverse events, Adverse events of special interest and 3 more. Started Jul 2022; status: active, not recruiting.
02
Drugs
apraglutide
03
Conditions
short bowel syndrome (SBS)intestinal failure (IF)
Beyond the preview
Go deeper on jRCT2031220255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220255.